TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11511328
Drug: Heliox therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox therapy
Study: 9696169
Drug: Ketorolac (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10 mg every 4 to 6 h as needed, up to four daily doses)
Study: 9696169
Drug: Acetaminophen-codeine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen-codeine (600 mg-60 mg every 4 to 6 h as needed, up to six daily doses)
Study: 47538
Drug: Leucocyte-poor blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-poor blood (L.P.B.)
Study: 31345462
Drug: Adjunctive sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive sertraline (400 mg/day for 2 weeks, then 200 mg/day for 12 weeks, tapered over 3 weeks)
Study: 31345462
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard therapy with 7-14 days of intravenous amphotericin B and oral fluconazole)
Study: 31345462
Drug: Adjunctive sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive sertraline
Study: 28906040
Drug: lokivetmab (1–3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: lokivetmab (1–3.3 mg/kg, monthly injectable)
Study: 28906040
Drug: ciclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciclosporin (5 mg/kg/once daily)
Study: 22734234
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (10 mg/d) and bicyclol (25 mg, tid.)
Study: 22734234
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (10 mg/d)
Study: 17115982
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 to 200 mg daily)
Study: 15095933
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (Plavix) combination therapy
Study: 15095933
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and warfarin combination therapy
Study: 9502626
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and subcutaneous heparin treatment
Study: 2656331
Drug: PSK immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK immunotherapy (n = 21)
Study: 27657997
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg daily for 12 weeks)
Study: 24143092
Drug: Advanced medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced medications
Study: 16261567
Drug: Guanfacine (noradrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (noradrenergic agonist)
Study: 2401176
Drug: Radical operation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical operation plus chemotherapy
Study: 2401176
Drug: Radical operation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical operation plus chemotherapy in Stage II and III lesions
Study: 6772449
Drug: Topical slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical slow-release nitroglycerin
Study: 6772449
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release nitroglycerin
Study: 6364030
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg I.V. indomethacin just after diagnosis
Study: 6364030
Drug: I.V. or
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. or oral indomethacin (ad libitum) after 48 hours
Study: 31430578
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (EST)
Study: 16041631
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% cream (LMX4)
Study: 7576976
Drug: [131I]MIBG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: [131I]MIBG treatment alone
Study: 2179782
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin 5000 units 2 hours before surgery and every 8 hours postoperatively (regimen I)
Study: 2179782
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin 5000 units every 8 hours preoperatively (between two and nine doses) and every 8 hours postoperatively (regimen II)
Study: 25978109
Drug: H2-rich water
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-rich water (0.9 L/day) for 10 weeks
Study: 21876446
Drug: dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose reduction
Study: 17076823
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg cortisol
Study: 17605632
Drug: Zoledronate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (4 mg, i.v.)
Study: 17605632
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg, i.v., for 2 consecutive days every 3 mo; n = 60)
Study: 17605632
Drug: Neridronate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (100 mg, i.v., for 2 consecutive days)
Study: 12391349
Drug: Eletriptan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 80 mg vs Sumatriptan 50 mg
Study: 12391349
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of eletriptan vs Sumatriptan
Study: 12391349
Drug: Eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 40 mg vs both Sumatriptan doses
Study: 10437990
Drug: Higher-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose methadone (mean dose 211 mg/d, range 110‐780 mg/d)
Study: 10437990
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mean dose 65 mg/d)
Study: 6986243
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine with antacid therapy
Study: 6986243
Drug: Oral cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cimetidine with antacids
Study: 29480853
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic preconditioning (RIPC) - induced by 4 times of 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper arm, followed by 5-min intervals of reperfusion at 1 hour before PCI therapy.
Study: 27172434
Drug: Transdermal T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal T gel (1.25 g, 2.5 g, 5.0 g, 10 g, or 15 g daily) plus acyline injections every 2 weeks
Study: 27172434
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections and transdermal gel
Study: 25209519
Drug: Ozenoxacin 1%
Normalized name: OZENOXACIN 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 1% ointment (single doses)
Study: 25209519
Drug: Ozenoxacin 1%
Normalized name: OZENOXACIN 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 1% ointment (multiple doses)
Study: 25209519
Drug: Ozenoxacin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 2% cream (multiple doses)
Study: 25209519
Drug: Ozenoxacin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 2% cream (multiple doses on intact and abraded skin)
Study: 23000583
Drug: LAB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAB group (LAB‐G)
Study: 23000583
Drug: LAB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAB with lactose group (L‐LAB‐G)
Study: 23000583
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C‐G)
Study: 18156660
Drug: Whey-protein supplement
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey-protein supplement (120 kcal, 30 g protein)
Study: 15726879
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg oral dose)
Study: 7805119
Drug: Consupren (Czech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consupren (Czech preparation of cyclosporin A)
Study: 19014072
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for OSA
Study: 10885237
Drug: Drip-infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip-infusion of Diprivan (1% propofol emulsion)
Study: 10885237
Drug: Syringe-pump administration
Normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe-pump administration of Diprivan (1% propofol emulsion)
Study: 8316057
Drug: Garlic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplementation (600 mg/d of garlic powder for two weeks)
Study: 27903994
Drug: Synbiotic supplement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic supplement, 1000 mg/d for 6 weeks
Study: 27903994
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules a day) for 6 weeks
Study: 19068205
Drug: Beta-blocker bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker bisoprolol (n=55)
Study: 19068205
Drug: Routine drugs
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drugs (ACE Inhibitors, diuretics, vasodilator drugs) (n=55)
Study: 16897997
Drug: S-1 (2-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (2-week administration followed by 1-week rest)
Study: 16897997
Drug: UFT (4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (4-week administration followed by 2-week rest)
Study: 9663830
Drug: Single-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose misoprostol (400 microg)
Study: 3947108
Drug: CQ PSK
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ PSK in alternate doses (Group B)
Study: 3947108
Drug: CQ +
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CQ + PSK in alternate doses (Group D)
Study: 19909829
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate injections (2 mg every 2 months, 3 mg every 3 months)
Study: 19909829
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate (3 mg)
Study: 19909829
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or IV placebo
Study: 12459940
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg/day for 48 weeks)
Study: 12459940
Drug: Etidronate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (200 mg/day for 2 weeks followed by 10-week medication-free periods)
Study: 10673950
Drug: Standard patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard patient treatment position for left‐sided tumours
Study: 10673950
Drug: 3-dimensional planning
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-dimensional planning with optimum treatment position for left‐sided tumours
Study: 14671611
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
Study: 3900301
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy alone
Study: 31383385
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral ibuprofen
Study: 31383385
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral ibuprofen
Study: 10223771
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral ibuprofen
Study: 24613450
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral alendronate (70 mg)
Study: 24613450
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (1-time 5 mg)
Study: 19909947
Drug: Levonorgestrel (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (1.5 mg) administered orally
Study: 19909947
Drug: Levonorgestrel (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (1.5 mg) administered vaginally
Study: 7500174
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy nutrient dense supplement provided by a dietitian
Study: 6349453
Drug: Real peritoneal
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real peritoneal dialysis (48 hours weekly, 1.5-hour cycle times, 2-litre exchanges by machine)
Study: 6349453
Drug: Sham peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham peritoneal dialysis (recycling the same 2 litres of 1.5% continuous ambulatory peritoneal dialysis fluid, 1.5-hour cycle times for 48 hours weekly)
Study: 27575034
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with triamcinolone (steroids)
Study: 27575034
Drug: Bupivacaine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine without steroids (control)
Study: 20717085
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose evaluation
Study: 20717085
Drug: Average fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average fractional dose
Study: 17713804
Drug: DHASCO-T capsules
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHASCO-T capsules at doses of 200 mg DHA per day
Study: 17713804
Drug: DHASCO-T capsules
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHASCO-T capsules at doses of 600 mg DHA per day
Study: 17713804
Drug: DHASCO-T capsules
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHASCO-T capsules at doses of 1,000 mg DHA per day
Study: 17713804
Drug: DHASCO-S capsules
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHASCO-S capsules at doses of 200 mg DHA per day
Study: 17713804
Drug: DHASCO-S capsules
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHASCO-S capsules at doses of 600 mg DHA per day
Study: 17713804
Drug: DHASCO-S capsules
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHASCO-S capsules at doses of 1,000 mg DHA per day
Study: 7808848
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms subunit vaccine
Study: 7808848
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms subunit vaccine
Study: 2766267
Drug: Psychoeducational preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational preparation 1‐2 days prior to surgery
Study: 2766267
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no psychoeducational preparation)
Study: 1130885
Drug: Clindamycin or
Normalized name: clindamycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin or Cephalothin (antibiotic therapy randomized, given intravenously prior to operation and for 5 days thereafter)
Study: 31918232
Drug: Single‐ or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐ or mixed‐gender group therapy (for women)
Study: 31918232
Drug: Mixed‐gender group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed‐gender group therapy (for men)
Study: 26202996
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (cognitive-behavioral therapy)
Study: 21447531
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of gelatin microspheres prepared with basic fibroblast growth factor (b‐FGF)
Study: 21447531
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without any topical treatment
Study: 16892912
Drug: Sequential and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential and multistage designs
Study: 17989536
Drug: Venom immunotherapy
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venom immunotherapy
Study: 15306668
Drug: No venom
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: No venom immunotherapy
Study: 8505011
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (11 mg natural progesterone)
Study: 8505011
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection (11 mg natural progesterone)
Study: 3476985
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel followed by 1% NaF gel daily for 2 weeks
Study: 3476985
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel followed by 1% NaF gel daily for 6 weeks supplemented twice with 8% SnF2 solution
Study: 18701540
Drug: Static resting
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static resting splints plus standardized occupational therapy
Study: 18701540
Drug: Standardized occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized occupational therapy alone
Study: 15808245
Drug: Strontium plaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium plaque brachytherapy (Sr90) using plaque I (8 mm diameter, 15 Gy dose in 54 minutes)
Study: 15808245
Drug: Strontium plaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium plaque brachytherapy (Sr90) using plaque II (4 mm diameter, 12.6 Gy dose in 11 minutes)
Study: 6365467
Drug: Bemetizide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemetizide (25 mg) + Triamterene (50 mg)
Study: 6365467
Drug: Cyclopenthiazide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopenthiazide (0.25 mg) + Potassium Chloride (600 mg)
Study: 27821627
Drug: Rituximab with
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab with standard therapy
Study: 22382410
Drug: Physical masking
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physical masking by spray-coating famotidine with ethyl cellulose
Study: 22382410
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both taste-masking methods
Study: 19302453
Drug: Individualized pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized pre-operative blood saving protocol (including strategies such as oral iron therapy, intravenous iron therapy, recombinant human erythropoietin alpha with i.v. iron, pre-operative autologous donation plus oral iron)
Study: 17967591
Drug: Enoximone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (50 mg or 75 mg tid for 1 week, then reduced to 25 mg or 50 mg tid)
Study: 1969066
Drug: Phosphate supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate supplementation (50 mg per day)
Study: 30399024
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (2000 IU/day)
Study: 23990341
Drug: Comparator (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (pooled intravenous standard therapies: semi-synthetic penicillin or vancomycin)
Study: 21375959
Drug: Low-dose ultrasound
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ultrasound (0.5 W/cm2) delivered at 1 MHz, pulsed pattern of 1:4, applied to periulcer skin weekly for up to 12 weeks alongside standard care.
Study: 21375959
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (low‐adherent dressings and compression therapy).
Study: 19926050
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg once daily for 1 week
Study: 19926050
Drug: Standard maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard maintenance dosage clopidogrel (75 mg)
Study: 17302062
Drug: Prunellae Oral
Normalized name: Prunella vulgaris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prunellae Oral Liquid (POL) based on classical therapy
Study: 17302062
Drug: Classical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical therapy alone
Study: 15566594
Drug: lornoxicam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam (8 mg administered intravenously every 12 hours for six doses)
Study: 2525023
Drug: Combined reflex-therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined reflex-therapy (including manipulations, neural therapy, and acupuncture)
Study: 2525023
Drug: Usual ambulant
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual ambulant medicamentous physiotherapeutic treatment
Study: 342295
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide 0.025% cream
Study: 31446845
Drug: Optimised cardiopulmonary
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised cardiopulmonary bypass strategy (closed Cortiva® heparin‐coated circuit, low systemic heparinisation, intraoperative cell salvage)
Study: 30948692
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (5 mg/day)